专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007076391A1 TGF-BETA BINDING COMPOSITIONS 审中-公开
标题翻译： TGF-βA结合组合物
公开(公告)号：WO2007076391A1
公开(公告)日：2007-07-05
申请号：PCT/US2006/062397
申请日：2006-12-20
申请人： ELI LILLY AND COMPANY , JONES, Bryan, Edward , PANCOOK, James, D. , ROWLINSON, Scott, William
发明人： JONES, Bryan, Edward , PANCOOK, James, D. , ROWLINSON, Scott, William
IPC分类号： C07K16/22 , A61K39/395
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-βl, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
摘要翻译：本发明提供了中和成熟的人TGF-β1，TGF-β2和TGF-β3的非常高亲和力的抗体或其抗原结合片段。本发明的抗体可用于治疗哺乳动物的细胞增殖性疾病。

2. 发明申请

WO2004050041A2 BUTYRYLCHOLINESTERASE VARIANTS THAT ALTER THE ACTIVITY OF CHEMOTHERAPEUTIC AGENTS 审中-公开
标题翻译：化学治疗剂的活性的丁基胆碱酯酶变体
公开(公告)号：WO2004050041A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038684
申请日：2003-12-04
申请人： APPLIED MOLECULAR EVOLUTION, INC. , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： A61K
CPC分类号： C12N9/18 , A61K38/00
摘要： The invention provides a butyrylchinesterase variant having the amino acid sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194 and 196,, or functional fragment thereof. In addition, the invention provides a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant selected from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, under conditions that allow conversion of a camptothecin derivative to a topoisomerase inhibitor. Further, the invention provides a method of treating cancer by administering to an individual an effective amount of a butyrylcholinesterase variant selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.
摘要翻译：本发明提供具有选自SEQ ID NO：4,6,8,10,12,14,24,26,28,30,32,34,36,38,40,42,44的氨基酸序列的丁酰基切割酶变体，46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94 ，96,98,100,102,104,106,108,110,112,114,116,118,120,122,124,126,128,130,132,134,136,138,140,142,144 ，146,148,150,152,154,156,158,160,162,164,166,168,170,172,174,176,178,180,182,184,186,188,190,192,194 和196 ,,或其功能片段。此外，本发明提供了一种通过使喜树碱衍生物与选自SEQ ID NO：2,4,6,8,10,12,14,26,26,26,26,26,26,26,26,26,26,26,26,26,28,26,26,26,26,26,26,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29 28，30，32，34，36，38，40，42，44，46，48，50，52，54，56，58，60，62，64，66，68，70， 78，80，82，84，86，88，90，92，94，96，98，100，102，104，106，108，110，112，114，116，118，120，122， 128，130，132，134，136，138，140，142，144，146，148，150，152，154，156，158，160，162，164， 178,180,182,184,186,188,190,192,194和196或其功能片段，在允许将喜树碱衍生物转化为拓扑异构酶抑制剂的条件下进行。此外，本发明提供了一种通过向个体施用有效量的丁酰胆碱酯酶变体来治疗癌症的方法，所述丁酰胆碱酯酶变体选自SEQ ID NO：2,4,6,8,10,12,14,24,26,28,30,40， 32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,80， 82，84，86，88，90，92，94，96，98，100，102，104，106，108，110，112，114，116，118，120，122，124，126，128， 132,134,136,138,140,142,144,146,148,150,152,154,156,158,160,162,164,166,168,170,172,174,176,178,180， 182,184,186,188,190,192,194和196或其功能片段，与丁酰胆碱酯酶相比表现出增加将喜树碱衍生物转化为拓扑异构酶抑制剂的能力。

3. 发明申请

WO2004092340A2 BUTYRYLCHOLINESTERASE VARIANT POLYPEPTIDES WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
标题翻译：具有增加的催化效率的丁二烯基酯改性聚异戊二烯和使用方法
公开(公告)号：WO2004092340A2
公开(公告)日：2004-10-28
申请号：PCT/US2004/011225
申请日：2004-04-09
申请人： APPLIED MOLECULAR EVOLUTION, INC. , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N
CPC分类号： C12N9/18 , A61K38/00 , C12Y301/01008
摘要： The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.
摘要翻译：本发明提供了具有增加的可卡因水解活性的丁酰胆碱酯酶变体以及相应的编码核酸。本发明还提供了水解可卡因类丁酰胆碱酯酶底物的方法以及用本发明变体治疗可卡因诱导病症的方法。

4. 发明申请

WO2002064796A3 BUTYRYLCHOLINESTERASE POLYPEPTIDE VARIANTS WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
公开(公告)号：WO2002064796A3
公开(公告)日：2002-08-22
申请号：PCT/US2001/050450
申请日：2001-12-21
申请人： APPLIED MOLECULAR EVOLUTION, INC. , UNIVERSITY OF NEBRASKA MEDICAL CENTER , LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N15/55
摘要： The invention provides twenty-five butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries of butyrylcholinesterase variants as well as libraries of the corresponding nucleic acids encoding butyrylcholinesterase variants. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

5. 发明申请

WO2002064796A2 BUTYRYLCHOLINESTERASE POLYPEPTIDE VARIANTS WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
标题翻译：具有增加的催化效率的丁基胆碱酯酶多肽变体及其使用方法
公开(公告)号：WO2002064796A2
公开(公告)日：2002-08-22
申请号：PCT/US2001/050450
申请日：2001-12-21
申请人： APPLIED MOLECULAR EVOLUTION, INC. , UNIVERSITY OF NEBRASKA MEDICAL CENTER , LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N15/55
CPC分类号： C12Q1/46 , A61K38/00 , C12N9/18 , C12Y301/01008
摘要： The invention provides twenty-five butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries of butyrylcholinesterase variants as well as libraries of the corresponding nucleic acids encoding butyrylcholinesterase variants. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
摘要翻译：本发明提供了具有增加的可卡因水解活性的二十五个丁酰胆碱酯酶变体以及相应的编码核酸。本发明还提供了丁酰胆碱酯酶变体的文库以及编码丁酰胆碱酯酶变体的相应核酸的文库。本发明还提供水解可卡因的丁酰胆碱酯酶底物的方法以及治疗可卡因诱导的病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式